Table 2 Demographic data of the respondents
Item | Answer | frequency, %(n = 397) |
|---|---|---|
Facility | Clinic | 126, 31.7% |
Community hospital | 194, 48.9% | |
University hospital | 77, 19.4% | |
Service | Neurology | 170, 42.8% |
Neurosurgery | 185, 46.6% | |
Internal medicine (other than neurology) | 9, 2.3% | |
Pediatrics | 9, 2.3% | |
Anesthesiology/Pain clinic | 16, 4.0% | |
Rehabilitation | 1, 0.3% | |
Ob-Gyn | 1, 0.3% | |
Otorhinolaryngology | 3, 0.8% | |
Psychiatry | 2, 0.5% | |
General medicine | 1, 0.3% | |
Age, yrs | 20 s | 3, 0.8% |
30 s | 32, 8.1% | |
40 s | 118, 29.7% | |
50 s | 131, 33.0% | |
60 s or older | 113, 28.5% | |
Years of headache practice | < 5 yrs | 24, 6.0% |
≥ 5 and < 10 yrs | 38, 9.6% | |
≥ 10 and < 20 yrs | 125, 31.5% | |
≥ 20 yrs | 210, 52.9% | |
Years of JHS membership | < 1 yr | 52, 13.1% |
≥ 1 and < 5 yrs | 70, 17.6% | |
≥ 5 and < 10 yrs | 73, 18.4% | |
≥ 10 yrs | 202, 50.9% | |
Boards | Headache | 232, 58.4% |
Neurology | 164, 41.3% | |
Neurosurgery | 181, 45.6% | |
Internal Medicine | 99, 24.9% | |
None | 23, 5.8% | |
CGRPmAb that is available at your facility | Erenumab | 244, 61.5% |
Galcanezumab | 337, 84.9% | |
Fremanezumab | 272, 68.5% |